Trial reportNeuro-oncology2026
Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial.
Trial report in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE-a 6-session, cognitive-behavioral, telehealth intervention-demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy.
methodsWe examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms.
resultsThe sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = -1.44, SE = 0.49, 95% CI [-2.50, -0.54]) and self-efficacy (indirect effect=-1.29, SE = 0.42, 95% CI [-2.16, -0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [-2.21, -0.74]) and self-efficacy (indirect effect = -0.95, SE = 0.32, 95% CI [-1.60, -0.36]).
conclusionThe NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers' self-efficacy in caregivers of patients with PMBT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.